11 completed, 1 terminated. 10 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 9, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow zamicastat: new trials by email Literature Review of zamicastat trials Research Report on zamicastat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of BIA 5-1058 in PAH Oral zamicastat - Pulmonary Arterial Hypertension | Phase 2 | Completed | Bial - Portela C S.A. | 20 | 2019-06-26 | 2023-09-01 |
| Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) Oral zamicastat - Pulmonary Arterial Hypertension | Phase 2 | Completed | Bial - Portela C S.A. | 33 | 2019-06-03 | 2024-10-15 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058 BIA 5-1058, Placebo - Cardiovascular Disease+Pulmonary Disease, Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 157 | 2018-05-28 | 2020-12-31 |
| Effect of BIA 5 1058 on Cardiac Repolarization BIA 5-1058, Placebo Oral Tablet, Moxifloxacin 400 mg - Cardiovascular Disease, Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 49 | 2018-04-09 | 2020-12-31 |
| Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil BIA 5-1058, Sildenafil - Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 20 | 2018-03-22 | 2021-08-06 |
| Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil BIA 5-1058, treprostinil - Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 20 | 2018-02-28 | 2020-12-19 |
| Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics BIA 5-1058, Warfarin - Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 26 | 2018-02-23 | 2021-08-06 |
| Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan BIA 5-1058, bosentan - Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 44 | 2018-02-06 | 2021-08-05 |
| Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 400 mg BIA 5-1058 - Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 15 | 2017-03-31 | 2021-08-05 |
| Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058 BIA 5-1058 - Pulmonary Arterial Hypertension | Phase 1 | Terminated | Bial - Portela C S.A. | 61 | 2015-10-12 | 2021-08-05 |
| Effect of Food on BIA 5-1058 BIA 5-1058 - Pulmonary Arterial Hypertension | Phase 1 | Completed | Bial - Portela C S.A. | 57 | 2015-07-20 | 2021-08-05 |
| Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058. BIA 5-1058, Placebo - Hypertension and Chronic Heart Failure | Phase 1 | Completed | Bial - Portela C S.A. | 124 | 2011-03-01 | 2016-01-05 |
Pulmonary Arterial Hypertension (11) · Cardiovascular Diseases (2) · Heart Failure (1) · Hypertension (1)
Germany (6) · United Kingdom (4) · Austria (2) · Italy (2) · Netherlands (2) · Portugal (2) · Spain (2) · Ukraine (1)
2015 (5), 2017 (3), 2018 (3)